Product Description
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular, Intravenous, Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | Germany | India | Indonesia | Ireland | New Zealand | Pakistan | Peru | Portugal | Russia | Taiwan | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Julio Ramirez
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Osteomyelitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02099240 |
PRESTO:Osteo | P1 |
Terminated |
Osteomyelitis |
2018-11-07 |
2024-11-27 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|